SM 20302
Alternative Names: SM-20302Latest Information Update: 30 Aug 2007
Price :
$50 *
At a glance
- Originator Sumitomo Pharmaceuticals
- Developer Nonindustrial source; Sumitomo Pharmaceuticals
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary thrombosis; Thrombosis
Most Recent Events
- 27 Sep 1999 Preclinical development for Coronary thrombosis in Japan (Unknown route)
- 27 Sep 1999 Two preclinical studies have been added to the Thromboses and Ischaemic Heart Disease pharmacodynamics sections ,
- 27 Sep 1999 Two preclinical studies have been added to the Thromboses pharmacodynamics section ,